PRLX 93936, a novel, small molecule with broad antitumor activity in vitro

A7 PRLX 93936 was identified as a potential anti-cancer therapeutic in a synthetic lethal screen against isogenic cell lines engineered to differentially express several oncogenes including activated RasV12. Subsequent testing against a series of normal and tumor cell lines derived from tumors with dissimilar causative mutations and limited treatment options, indicated potent and selective activity against 29 out 36 (50% inhibition at